Adjuvant radiotherapy after breast-conserving surgery has become an integral part of the treatment of breast cancer. In recent years, the development of radiotherapy technology has made great progress in this field, including the comparison of the curative effects of various radiotherapy techniques and the performance of the segmentation times. The choice of radiotherapy technology needs to be co-determined by clinical evidence practice and evaluated for each individual patient to achieve precision radiotherapy. This article discusses the treatment effects of different radiotherapy, techniques, the risk of second cancers and short-range radiation therapy techniques after breast-conserving surgery such as hypo fractionated whole breast irradiation and accelerated partial breast irradiation. The choice of radiotherapy regimen needs to be based on the individual condition of the patient, and the general principle is to focus on the target area and reduce the irradiation of the normal tissues and organs. Short-range radiotherapy and hypofractionated are superior to conventional radiotherapy and are expected to become the mainstream treatment after breast-conserving surgery.
Most patients with advanced gastric cancer were treated with palliative therapy, which had a poor curative effect and a short survival time. In recent years, the clinical research of immune checkpoint inhibitors in advanced gastric cancer has made a breakthrough and has become an important treatment for advanced gastric cancer. The modes of immune checkpoint inhibitors in the treatment of advanced gastric cancer include single drug, combined chemotherapy, radiotherapy, and multiple immune drug combination therapy, among which combination therapy shows better clinical efficacy, and a large number of trials are currently exploring more effective combination therapy programs. In this paper, the new clinical research progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer is reviewed, with an emphasis on combination therapy.
Glioblastoma (GBM) is an extremely aggressive brain tumor. Its standard treatment currently involves surgery followed by radiotherapy and temozolomide. However, recurrence is frequently unavoidable, and the effect of various treatments is not ideal due to numerous inherent obstacles. Immunotherapy has demonstrated promising prospects in the management of various cancers. Despite several preclinical studies have shown that immunotherapy may improve the survival in GBM mouse model, the results from completed clinical trials reveal that it brings only limited benefit for GBM patients to date. Interestingly, several studies have demonstrated that radiotherapy not only eliminates tumor cells by inducing DNA damages but also improves the effect of immunotherapy by modulating immune response. Combining immunotherapy with radiotherapy for GBM has been evaluated extensively. Herein, we present the immunotherapy applied in GBM and highlight the importance of tumor microenvironment in immunotherapy for GBM. Moreover, we review the preclinical and clinical data for applying immunotherapy combined with radiotherapy for GBM. Finally, we also discuss the challenges facing combined treatment of immunotherapy and radiotherapy for GBM and further research aspects in the discussion section.
Postoperative adjuvant radiotherapy plays an important role in the treatment of patients with breast cancer. With the continuous development of radiotherapeutic technologies, the requirements for radiotherapeutic accuracy are increasingly high. The accuracy of target volume and organ at risk delineation significantly affects the effect of radiotherapy. Automatic delineation software has been continuously developed for the automatic delineation of target areas and organs at risk. Automatic segmentation based on an atlas and deep learning is a hot topic in current clinical research. Automatic delineation can not only reduce the workload and delineation times, but also establish a uniform delineation standard and reduce inter‑observer and intra‑observer differences. In patients with breast cancer, especially in patients who undergo left breast radiotherapy, the protection of the heart is particularly important. Treating the whole heart as an organ at risk cannot meet the clinical needs, and it is necessary to limit the dose to specific cardiac substructures. The present review discusses the importance of automatic delineation of target volume and cardiac substructure in radiotherapy for patients with breast cancer.
Targeted drug therapy plays an important role in the clinical application of non-small cell lung cancer, especially adenocarcinoma. However, for patients with advanced disease, drug resistance after targeted therapy, unclear target, and other reasons that cannot or do not want surgery, the combination of chemotherapy, radiotherapy, immunity, etc. is often used. The synergistic effect of targeted drugs and radiotherapy in non-small cell lung cancer has shown good clinical efficacy. This article reviews the clinical progress of targeted drug therapy combined with radiotherapy in advanced non-small cell lung cancer in recent years, in order to provide new ideas for further clinical research of this treatment mode.
Boron neutron capture therapy (BNCT) is a unique radiotherapy modality that targets and destroys selectively tumor cells that have absorbed boron, while leaving surrounding healthy cells unharmed. Over the course of the last nearly 40 years, several clinical studies of BNCT for melanoma have been conducted in many countries. The results of clinical studies are encouraging, suggesting that BNCT may be a potentially effective method for treating melanoma. In this work, we review the outcomes of clinical study of BNCT for melanoma. Moreover, we provide a concise overview of advancements in accelerator-based neutron source and boron delivery agent (BDA) applied to BNCT for melanoma. Finally, we discuss the areas for further research focus regarding BNCT for melanoma.